Business Context and Reporting Period
Company: Thermo Electron Corporation (now Thermo Fisher Scientific Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 3, 2004
Business Overview: The company develops and manufactures analytical instrumentation for laboratory and industrial customers. Following the decision to sell its Optical Technologies segment (Spectra-Physics), continuing operations are organized into two segments: Life and Laboratory Sciences and Measurement and Control. Results for prior periods have been restated to reflect Spectra-Physics as a discontinued operation.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 3, 2004 |
Three Months Ended June 28, 2003 |
Six Months Ended July 3, 2004 |
Six Months Ended June 28, 2003 |
|---|---|---|---|---|
| Revenues | $525,309 | $467,268 | $1,050,341 | $921,896 |
| Operating Income | $58,970 | $49,746 | $111,844 | $92,647 |
| Operating Margin | 11.2% | 10.6% | 10.6% | 10.0% |
| Net Income | $91,080 | $53,139 | $134,202 | $89,566 |
| Diluted EPS (Total) | $0.54 | $0.32 | $0.79 | $0.54 |
| Cash from Operations | N/A | N/A | $105,003 | $66,065 |
| Cash & Equivalents | $306,617 | $264,442 | $306,617 | $264,442 |
| Total Debt | $259,600 | N/A | $259,600 | N/A |
Note: Net Income includes significant gains from discontinued operations ($40.5M for Q2, $43.96M for YTD). Income from Continuing Operations was $50.6M for Q2 and $90.2M for YTD.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 12% in Q2 2004 and 14% YTD compared to 2003. Growth was driven by a 3% increase in organic demand, favorable currency translation ($15M in Q2), and acquisitions (USCS, Jouan, LMSi).
- Profitability: Operating income margin improved to 11.2% in Q2 2004 from 10.6% in Q2 2003, primarily due to lower restructuring costs ($1.2M in 2004 vs. $4.7M in 2003) and a lower cost base from prior restructuring.
- Discontinued Operations Impact: Net income was significantly boosted by the sale of Spectra-Physics. A $38.5M tax benefit was recorded in Q2 2004 related to the sale, and the segment generated $40.5M in net income for the quarter.
- Acquisitions: The company acquired US Counseling Services (USCS) in April 2004 for approximately $78.8M, adding $66.9M to goodwill. Annual amortization expense increased by $6.9M due to this acquisition.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash, investments ($371.8M), proceeds from the Spectra-Physics sale ($300M), and operating cash flow to meet capital requirements for at least the next 24 months.
- Restructuring: The company expects to incur an additional $1.3M in restructuring costs in 2004. In Q3 2004, the company plans headcount reductions of approximately 200 employees at a cost of $5M.
- Share Repurchases: The Board authorized an additional $100M for share repurchases on July 22, 2004. $40.5M remained under the previous authorization as of July 3, 2004.
- Risks:
- Litigation: The company is a defendant in a patent-infringement lawsuit by the Lemelson Foundation; an unfavorable outcome could have a material adverse effect.
- Goodwill Impairment: With $1.48B in goodwill, the company faces risk if future cash flows decline or market conditions worsen.
- Currency: International revenues account for ~69% of total revenues; a strengthening U.S. dollar would unfavorably affect reported revenues.
Investor Verification Checklist
- Discontinued Operations: Verify the sustainability of earnings by excluding the one-time $38.5M tax benefit and $40.5M net income from the Spectra-Physics sale.
- Acquisition Integration: Monitor the integration of USCS and Jouan, specifically regarding the impact of increased amortization ($6.9M and $6.2M annually) on future margins.
- Restructuring Costs: Track the execution of the planned Q3 2004 headcount reductions ($5M cost) and the completion of 2003 restructuring plans.
- Litigation Exposure: Review updates on the Lemelson Foundation patent lawsuit for potential material liabilities.
- Currency Sensitivity: Assess the impact of foreign exchange rates on future revenue, given the 69% international exposure.